Add to ORKGUnknown onset time is a common contraindication for anti-thrombolytic treatment of ischaemic stroke. T2 relaxation-based signal changes within the lesion can identify patients within or beyond the 4.5-hour intravenous thrombolysis treatment-window. However, now that intra-arterial thrombolysis is recommended between 4.5 and 6 hours from symptom onset and mechanical thrombectomy is considered safe between 6 and 24 hours, there are three treatment-windows to consider. Here we show a cumulative ordinal regression model, incorporating the T2 relaxation time, predicts the probabilities of a patient being within one of the three treatment-windows and is more accurate than signal intensity changes from T2 weighted images
Background and Purpose—Toward the goal of designing a clinical trial using imaging parameters to tre...
Introduction: In acute stroke, the DWI-FLAIR mismatch allows for the identification of patients elig...
Background: Intravenous thrombolysis (IVT) plays a prominent role in the treatment of acute ischemic...
Unknown onset time is a common contraindication for anti-thrombolytic treatment of ischaemic stroke....
Background: T2 relaxation-based magnetic resonance imaging (MRI) signals may provide onset time for ...
Background and objective:In hyperacute ischaemic stroke, T2 of cerebral water increases with time. Q...
Importance: Pooled analysis of randomized controlled trials of intravenous thrombolysis shows no st...
The apparent diffusion coefficient (ADC) of cerebral water, as measured by diffusion MRI, rapidly de...
BACKGROUND: Wake-up stroke (WUS) represents 25% of all ischemic strokes. There is conflicting evide...
Introduction: Mechanical thrombectomy within 6 h after stroke onset improves the outcome in patients...
Introduction: Radiological thrombus characteristics are associated with patient outcomes and treatme...
Background: Intravenous thrombolysis with alteplase within a time window up to 4.5 h is the only app...
BACKGROUND: Extending the therapeutic window for thrombolysis is an important strategy in maximizing...
Many ischaemic stroke patients are ineligible for thrombolytic therapy due to unknown onset time. Q...
IMPORTANCE Pooled analysis of randomized controlled trials of intravenous thrombolysis shows no stat...
Background and Purpose—Toward the goal of designing a clinical trial using imaging parameters to tre...
Introduction: In acute stroke, the DWI-FLAIR mismatch allows for the identification of patients elig...
Background: Intravenous thrombolysis (IVT) plays a prominent role in the treatment of acute ischemic...
Unknown onset time is a common contraindication for anti-thrombolytic treatment of ischaemic stroke....
Background: T2 relaxation-based magnetic resonance imaging (MRI) signals may provide onset time for ...
Background and objective:In hyperacute ischaemic stroke, T2 of cerebral water increases with time. Q...
Importance: Pooled analysis of randomized controlled trials of intravenous thrombolysis shows no st...
The apparent diffusion coefficient (ADC) of cerebral water, as measured by diffusion MRI, rapidly de...
BACKGROUND: Wake-up stroke (WUS) represents 25% of all ischemic strokes. There is conflicting evide...
Introduction: Mechanical thrombectomy within 6 h after stroke onset improves the outcome in patients...
Introduction: Radiological thrombus characteristics are associated with patient outcomes and treatme...
Background: Intravenous thrombolysis with alteplase within a time window up to 4.5 h is the only app...
BACKGROUND: Extending the therapeutic window for thrombolysis is an important strategy in maximizing...
Many ischaemic stroke patients are ineligible for thrombolytic therapy due to unknown onset time. Q...
IMPORTANCE Pooled analysis of randomized controlled trials of intravenous thrombolysis shows no stat...
Background and Purpose—Toward the goal of designing a clinical trial using imaging parameters to tre...
Introduction: In acute stroke, the DWI-FLAIR mismatch allows for the identification of patients elig...
Background: Intravenous thrombolysis (IVT) plays a prominent role in the treatment of acute ischemic...